Table 1.
GI disease correlates with decreased fecal archaea.
| Archaea pos | Archaea neg | Odds ratio | 2.5/97.5% interval | p-value | |||
|---|---|---|---|---|---|---|---|
| Categorization across disease groups | |||||||
| Controls | 18/40 | (45.0%) | 22/40 | (55.0%) | |||
| Irritable bowel disease D/M | 20/75 | (26.7%) | 55/75 | (73.3%) | 0.29 | (0.09–0.88) | 0.03 |
| Irritable bowel disease C | 7/21 | (33.3%) | 14/21 | (66.7%) | 0.24 | (0.05–1.02) | 0.06 |
| Ulcerative colitis | 5/18 | (27.8%) | 13/18 | (72.2%) | 0.27 | (0.06–1.11) | 0.08 |
| Categorization across patient characteristics | |||||||
| Antibiotic intake | 24/36 | (66.7%) | 47/68 | (69.1%) | 1.53 | (0.55–4.60) | 0.43 |
| PPI intake | 13/34 | (38.2%) | 33/69 | (47.8%) | 0.53 | (0.20–1.35) | 0.18 |
| Biofilm presence | 24/50 | (48.0%) | 61/104 | (58.7%) | 0.69 | (0.25–1.82) | 0.44 |
Multivariate Logistic Regression of Archaea Status relative to Controls (above). Multivariate Logistic Regression of Archaea Status relative to medication and biofilm presence (below): intake of medication depending on archaeal status, group sizes vary due to available medication histories.